Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mouse Models of Cancer Study

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Performance characteristics of three <i>Brucella canis</i> serological assays in the United States.

Frontiers in veterinary science·2025

Same author

Household Transmission of SARS-CoV-2 from Humans to Pets, Washington and Idaho, USA.

Emerging infectious diseases·2022

Same author

Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101.

Proceedings of the National Academy of Sciences of the United States of America·2022

Same author

The Outcome and Economic Viability of Embryo Production Using IVF and SOV Techniques in the Wagyu Breed of Cattle.

Veterinary sciences·2020

Same author

Alternative Methods to Reduce, Refine, and Replace the Use of Animals In the Development and Testing of Veterinary Biologics in The United States; a Strategic Priority.

Procedia in vaccinology·2020

Same author

Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens.

Clinical immunology (Orlando, Fla.)·2017

Search research articles

Related Experiment Video

Updated: Jul 28, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the

Richard E Hill¹, David M de Avila, Kevin P Bertrand

¹Department of Animal Sciences, Washington State University, Pullman, Washington 99164, USA.

Experimental Biology and Medicine (Maywood, N.J.)

|July 24, 2003

Summary

Immunizing mice against luteinizing hormone-releasing hormone (LHRH) reduced testosterone but did not increase lifespan or decrease tumor weight. This prostate cancer model showed increased tumor aggressiveness and lung metastasis in LHRH-immunized mice.

More Related Videos

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: Jul 28, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Area of Science:

Oncology
Immunology
Endocrinology

Background:

Prostate cancer growth is initially androgen-dependent.
Androgen-independent prostate cancer represents a therapeutic challenge.
The transgenic adenocarcinoma mouse prostate (TRAMP) model is widely used to study prostate cancer.

Purpose of the Study:

To evaluate the effect of immunization against luteinizing hormone-releasing hormone (LHRH) on prostate cancer progression in TRAMP mice.
To compare LHRH immunization with surgical castration in modulating prostate cancer development.

Main Methods:

TRAMP mice were immunized with a cocktail vaccine containing LHRH fusion proteins at 4 or 8 weeks of age.
Groups included LHRH-immunized, surgically castrated, and intact control mice.
Measurements included testosterone levels, testicular weight, tumor weight, lifespan, and incidence of lung metastasis.

Main Results:

LHRH immunization successfully induced antibodies against LHRH and reduced testicular weight and serum testosterone.
Tumor weight was variable and not significantly affected by LHRH immunization or castration.
Lifespan was not extended in either the LHRH-immunized or castrated groups compared to intact controls.
A higher incidence of lung tumors (35%) was observed in LHRH-immunized mice, suggesting increased tumor aggressiveness.

Conclusions:

Immunization against LHRH in TRAMP mice effectively suppressed testosterone but did not prevent prostate cancer progression.
The observed increase in lung metastasis indicates that LHRH immunization may promote a more aggressive, potentially androgen-independent, form of prostate cancer.
The TRAMP model with LHRH immunization may serve as a valuable tool for studying androgen-independent prostate cancer and evaluating novel therapeutic strategies.